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ABSTRACT: Elevated chemokine receptor Ccr7 is observed in knee osteoarthritis (OA) and associated with severity of symptoms. In this
study, we confirmed that CCR7 protein expression is elevated in synovial tissue from OA patients by immunohistochemical staining. We
then investigated whether Ccr7 deficiency impacted structural and functional joint degeneration utilizing a murine model of OA. OA-like
disease was induced in male C57BL/6 and Ccr7-deficient (Ccr7/) mice by destabilization of the medial meniscus (DMM). Functional
deficits were measured by computer integrated monitoring of spontaneous activity every 4 weeks after DMM surgery up 16 weeks. Joint
degeneration was evaluated at 6 and 19 weeks post-surgery by histopathology, and subchondral bone changes analyzed by microCT.
Results showed reduction in locomotor activities in DMM-operated C57BL/6 mice by 8 weeks, while activity decreases in Ccr7/ mice
were delayed until 16 weeks. Histopathologic evaluation showed minimal protection from early cartilage degeneration (p¼0.06) and
osteophytosis (p¼ 0.04) in Ccr7/ mice 6 weeks post-DMM compared to C57BL/6 controls, but not at 19 weeks. However, subchondral
bone mineral density (p¼0.03) and histologic sclerosis (p¼ 0.02) increased in response to surgery in C57BL/6 mice at 6 weeks, while
Ccr7/ mice were protected from these changes. Our results are the first to demonstrate a role for Ccr7 in early development of
functional deficits and subchondral bone changes in the DMM model. Understanding the mechanism of Ccr7 receptor signaling in the
initiation of joint pathology and disability will inform the development of innovative therapies to slow symptomatic OA development after
injury. Published 2017. This article is a U.S. Government work and is in the public domain in the USA. J Orthop Res 36:864–875, 2018.
Keywords: osteoarthritis; chemokines; animal model; bone remodeling; murine behavioral analysis
Osteoarthritis (OA) is characterized by pathologic
changes throughout the joint including cartilage de-
generation, subchondral bone remodeling, osteophyto-
sis, and synovial inflammation.1 In 2005, 27 million
individuals were estimated to be affected in the United
States, and this number is growing.2 Current manage-
ment provides only partial symptomatic relief without
halting progression of structural changes or joint
dysfunction. Total joint replacement (TJR), the only
definitive treatment, is reserved for patients with
advanced degeneration.
Patients seek treatment for severity of their joint
pain, while disease is diagnosed by extent of structural
changes (joint space narrowing and osteophytosis)
identified on radiographs. However, there is poor
correlation between radiographic features of OA, and
symptom severity and disability.3 Synovitis, which is
not visible on plain radiographs, has been linked to rate
of cartilage erosion4–7 and pain in OA.4,6,8 Although
variable,9–11 synovitis occurs throughout the course of
disease, from early to advanced stages.4,5 Recent work
shows a relationship between synovitis and develop-
ment of pain sensitization over 2 years.12 Although
these findings suggest that targeting synovitis might
reduce pain in knee OA,12–14 molecular mechanisms
driving synovitis in OA are still poorly understood.
To identify potential therapeutic targets associated
with synovitis and symptoms, we previously analyzed
the synovial transcriptome in patients with early-stage
knee OA.4 In patients who exhibited synovial cellular
infiltration, as evidenced by synovial biopsy, a chemo-
kine signature was identified. This included the che-
mokine receptor Ccr7 and its two natural ligands
(Ccl19 and Ccl21).4 Ccr7 is expressed by a variety of
cells including lymphocytes,15,16 dendritic cells,17 mac-
rophages,18 and synovial fibroblasts.19 This receptor
and its ligands mediate homing of lymphocytes to
secondary lymphoid organs under homeostatic condi-
tions,20 while in chronic inflammation they facilitate
migration of leukocytes and endothelial cells.21 In two
murine OA models, transcriptional up-regulation of
Ccl19 and Ccl21 in joint tissues was reported.22,23 In
addition, we reported associations between synovial
Ccr7 and Ccl19 mRNA expression and severity of knee
symptoms in two separate cohorts of patients.4,24 In
Conflicts of interest: CRS reports consulting for Bayer, Inc. and
research funding from Baxalta, Inc. unrelated to this manu-
script. AMM reports consulting for GIBH and Ferring. All other
authors report no conflict of interest related to this manuscript.
Grant sponsor: Rehabilitation Research and Development
Service; Grant numbers: RX001757, R21-AR-067916-01; Grant
sponsor: National Institute of Arthritis and Musculoskeletal and
Skin Diseases; Grant numbers: AR-007442, K01AR070328
R01AR064251, T32 AR-007442; Grant sponsor: Penn Center for
Musculoskeletal Disorders; Grant number: P30-AR06919.
Correspondence to: Carla R. Scanzello (T: (215) 823-58005666;
F: (215) 662-4500; E-mail: cscanz@upenn.edu)
Published 2017. This article is a U.S. Government work and is in the public
domain in the USA.
864 JOURNAL OF ORTHOPAEDIC RESEARCH1 MARCH 2018
the current study, we investigated Ccr7 protein ex-
pression in patients, and tested the effect of Ccr7
deficiency on structural and functional features of




Synovial membrane specimens were collected from the
suprapatellar pouch from 14 patients with degenerative
meniscal tears, 13 advanced knee OA and eight asymptom-
atic donors through IRB-approved bio-repositories at Rush
University Medical Center (RUMC), Chicago, IL (Table 1).
Meniscal tear patients were 21 years or older undergoing
arthroscopic partial meniscectomy; inflammatory arthritis
and avascular necrosis were excluded. Cartilage integrity
was evaluated intra-operatively according to Outerbridge25
(Table 1, and4,26). Radiographic OA was assessed by
Kellgren–Lawrence (K–L) score.27 Advanced OA patients
were undergoing total knee replacement (TKR) with a K–L
score of 3–4 on pre-operative knee films. Synovial membrane
was also collected within 24-h post-mortem from organ
donors with no history of arthritis or joint symptoms (Gift of
Hope Organ and Tissue Donor Network, Elmhurst, IL).
Gross degenerative changes were evaluated by a pathologist,
based on modified Collins grade.28
CCR7 Immunostaining in Human OA and Meniscal Injury
CCR7 expression in human synovial membrane was exam-
ined by routine immunohistochemical (IHC) staining using a
monoclonal anti-human CCR7 antibody (ab65851, Abcam,
Cambridge MA). Staining specificity was confirmed by utiliz-
ing an isotype-matched immunoglobulin control (ab125938,
Abcam), and was quantified on 10 images (NIS-Elements
AR, Nikon Instruments Inc., Melville, NY). Image analysis
involved defining five regions of interest (ROIs, each
2.5 10mm2 including lining and sub-lining) on a single
section per patient. Red thresholds were set uniformly to
highlight positively stained areas, and background was set
by comparison to isotype matched controls. Area positively
stained in each ROI was summed and reported as a fraction
of total area analyzed (1.25 106mm2).
Murine Destabilization of the Medial Meniscus (DMM) Model
Mice lacking expression of Ccr7 (B6.129P2(C)-Ccr7TM1Rfor/J
or Ccr7/)29 were obtained from Jackson Laboratory (Bar
Harbor, Maine), and had been backcrossed onto the C57BL/6
background for at least eight generations prior to purchase.
C57BL/6 mice (Jackson Laboratory) were used as wild-type
(WT), congenic controls. Institutional Animal Care and Use
Committees at the University of Pennsylvania and CMC
Veteran Affairs Medical Center approved all animal experi-
ments. Mice were housed in a pathogen-free facility
with water and food ad libitum and 12:12 light:dark cycle.
10–12-week-old male mice were anesthetized using ketamine
and xylazine prior to surgery. Animals were subjected to
medial arthrotomy of the right knee, and the anterior medial
meniscotibial ligament (MMTL) was severed leading to
destabilization of medial meniscus (DMM).30 Sham-operated
controls underwent arthrotomy, but the MMTL was left
intact. Naive (age-matched un-operated) controls from both
strains were also evaluated. If animals displayed any signs
of distress post-surgery, they were treated with buprenor-
phine for up to 72h. Animals were euthanized by carbon
dioxide inhalation at experimental end points. Groups,
endpoints, and outcomes measured are presented in Figure 1.
Functional disease outcomes were evaluated by longitudinal
activity monitoring up to 16 weeks post-surgery. Structural
disease outcomes were evaluated by microCT analysis of
subchondral bone and histopathologic analysis of cartilage,
bone, and synovium at 6 weeks post-DMM (early disease)
and 19 weeks post-DMM (late disease). Synovial inflamma-
tion was evaluated by gene expression 1, 2, and 4 weeks
post-surgery.
Functional Assessment of Post-Surgical Behavior
Changes in spontaneous behaviors (climbing, locomotion,
grooming, rearing, eating, drinking) were assessed using the
laboratory animal behavior observation registration and
analysis system (LABORASTM, Metris, Netherlands).34
Behavior was measured pre-surgery (time 0), and post-
surgery every 4 weeks to 16 weeks (minimum seven mice per
group). Two mice per day (one mouse/platform) were ana-
lyzed in 16-hour sessions between 4pm and 8am. The first
2h of data were excluded from final analyses to allow mice to
acclimatize to the testing environment. Weight was mea-
sured prior to each assessment. Nineteen weeks post-
surgery, mice were sacrificed and knee joints dissected. A
subgroup of knees (n¼ 5 per treatment group) were scanned
by microCT, and all knees were processed and analyzed
histologically as described below.
MicroCT Assessment of Subchondral Bone in the Murine DMM
Model
Knee joints (n¼ 5 per group) obtained post-mortem from
mice 19 weeks post-surgery (Fig. 1) were scanned prior to
decalcification (VivaCT 40 microCT scanner, Scanco-Medical
USA, Wayne, PA. Voxel size¼ 10.5mm, energy¼ 55kV,
Table 1. Characteristics of Patients Contributing Synovial Tissues for CCR7 Analysis
Asymptomatic Donors Meniscal Arthroscopy Advanced Knee OA
N¼ 8 14 13
Age 60.0 (27.5–62.5) 42.3 (33.2–47.2) 60.0 (57.0–69.5)a
BMI N/A 28.5 (27.8–34.6) 38.0 (31.6–42.6)a
Outerbridge/Collin’s Grade, 2 (0.25-3) 2 (2–3) 4 (4–4)a
Kellgren–Lawrence Stage N/A 1.5 (0.75–2) 4 (3.5–4)a
N/A, Not available.
Median (Interquartile range).
Outerbridge grade for meniscal arthroscopy and advanced OA patients, modified Collins grade for asymptomatic donors. a
aAdvanced knee OA compared to meniscal arthroscopy patients: Age p¼0.01, BMI p¼0.03, outerbridge and Kellgren–Lawrence
p<0.0001 (Mann–Whitney).
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intensity¼ 145mA, and integration time¼ 300ms). To assess
subchondral bone structure, the medial epiphysis of the
proximal tibia was chosen as the region of interest (ROI) in a
three-dimensional reconstructed coronal view. The ROI was
manually contoured selecting every 10th slice, including the
calcified cartilage and extending to the distal edge of the
growth plate (spanning 100mm). Ten percent of the medial
and lateral width of the MTP was excluded to avoid
osteophytes. Slices were spliced together to create a volume
of interest in which bone volume fraction (%BV/TV) and bone
mineral density (mgHA/cm3) were assessed. Additional
groups of five mice from each strain were euthanized at
10–12 weeks of age (time 0, unoperated), and 6 weeks post-
surgery for microCT analysis, and compared to 19 weeks.
Histopathologic Evaluation of Structural Joint Pathology
After scanning, knee joints from early (6 weeks), and late
(19 weeks) post-surgical time points were processed, embed-
ded, and sectioned for histopathologic assessment (Fig. 1).
Cartilage degradation was scored on toluidine-blue stained
sections using the modified OARSI score31,32 by a board-
certified veterinary pathologist (Dr. Allison Bendele, Bolder
BioPATH Inc., Boulder, CO) blinded to strain and treatment.
Briefly, each cartilage surface (medial tibial plateau, medial
femoral condyle, lateral tibial plateau, and lateral femoral
condyle) was divided into three zones: Inner, middle, and
outer thirds. Each zone was assigned a score in the range of
0–5 depending on severity of cartilage erosion, so that the
maximal score per surface¼ 15. Scores for each surface were
then summed to obtain a total score (maximum¼ 60). Osteo-
phyte size was measured using an ocular micrometer at the
medial tibial plateau and femoral condyle, and the largest
recorded. Subchondral bone sclerosis was scored on the
medial tibia (0¼normal to 5¼ severe), and synovial hyper-
plasia and sub-lining inflammation evaluated superior to the
medial meniscus using published scales.32,33
Molecular Assessment of Inflammation
Anterior synovial membrane and fat pad were harvested
together from both strains at baseline (10–12 weeks old), 1,
2, and 4 weeks post-DMM (Fig. 1). Tissues were dissected
from 20 to 30 mice per time point, and tissues from 4 to 5
mice were pooled together for each sample to obtain adequate
mRNA. This resulted in 5–6 samples analyzed per time
point. cDNA was synthesized by routine methods, and tran-
scripts quantified using the QX200TM Droplet DigitalTM PCR
(BioRad, Hercules, CA). Primers specific for CD68 (monocyte/
macrophage marker) were utilized for amplification, levels
expressed relative to TATA-box binding protein (TBP) tran-
scripts, and the operated side (right) was compared to the
unoperated side (left).
Statistical Analysis
Data were summarized by median and interquartile range
(IQR). For comparison of patient characteristics (Table 1),
Mann–Whitney U-tests were utilized. When comparing mul-
tiple groups, non-parametric Kruskal–Wallis ANOVA test
was applied, followed by individual pairwise Mann–Whitney
U-tests. The Bonferoni correction for multiple comparisons
was applied to assess statistical significance. CD68 mRNA
levels were compared between operated and contra-lateral
control limbs using Wilcoxon’s matched-pair signed rank
test. Linear mixed effects models were applied to test
whether trends in activity over time differed between
Figure 1. Schematic for the experiments included in this study. Function: Mice underwent activity monitoring on the LABORASTM
platforms pre-operatively, and then underwent DMM or sham surgery, or were left unoperated/na€ve (n¼7–10 mice per treatment
group). Activity was measured every 4 weeks up to 16 weeks post-operatively. Structure: Mice were then sacrificed at 19 weeks post-
operatively for micro CT (n¼ 5) and histology (n¼7–10) of cartilage and bone structure. Additional mice (n¼ 5 per group) were
subjected to DMM or sham (or na€ve), and then sacrificed 6 weeks post-surgery for structural analysis at an earlier stage of disease.
Inflammation: Another set of mice underwent DMM surgery, and then were sacrificed in groups of 20–30 at 1, 2, and 4 weeks post-
DMM. The anterior synovium and intra-articular fat pad were dissected together, and then tissues from 4 to 5 mice pooled per sample
resulting in 5–6 samples per time point. mRNA was extracted and analyzed as described.
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strains. Subject-specific random effects were included to
account for repeated measures, and the quadratic term of
time was included to capture nonlinear trends. Trend differ-
ences were assessed by the interactions of strain with time
and time squared. Within each strain, the Wilcoxon signed-
rank test was used to test differences from baseline activity
at each post-operative time. Statistical analyses were per-
formed in Prism 6.0 (GraphPad) and SAS 9.4 (SAS Institute,
Cary NC).
RESULTS
CCR7 Expression in Human Synovial Membrane
Presence of CCR7 protein expression was confirmed by
IHC staining of synovial biopsies, comparing asymp-
tomatic donors to patients with advanced knee OA and
patients undergoing arthroscopic partial meniscectomy
for degenerative meniscal pathology. Patient character-
istics are presented in Table 1. All but two arthroscopy
patients had intra-operative signs of mild-moderate
cartilage integrity loss consistent with early-stage OA.
These two patients had normal cartilage despite having
degenerative meniscal tears. Arthroscopy patients were
younger than the other groups and had a lower BMI
than those with advanced OA.
Representative CCR7-staining is depicted in
Figure 2A. Both arthroscopy and advanced knee OA
patients demonstrated CCR7 positivity in the synovial
lining layer, endothelium and peri-vascular inflamma-
tory infiltrates when present. Quantitative image
analysis (Fig. 2B) demonstrated significantly more
staining in meniscal arthroscopy patients than con-
trols (median % area stained, IQR¼11.1%, 5.4–18.4
vs. controls: 0.74%, 0.05–2.22, p¼0.008). Results were
unchanged when the two patients in the arthroscopy
group with normal cartilage were excluded (11.1%,
5.8–18.4). Advanced OA patients demonstrated inter-
mediate levels of CCR7 (6.42%, 2.36–10.25, p¼0.03, ns
with Bonferoni correction). Although this group was
also expected to be higher than controls, this differ-
ence was not statistically significant perhaps due to
small sample size.
Spontaneous Behavior in the Two Strains at Baseline and
Post-Surgery
Decreases in spontaneous activities have been associ-
ated with pain and cartilage degeneration in WT mice
post-DMM.35 Therefore, we investigated whether
spontaneous activity differed between strains. Activity
was measured overnight at 4-week intervals, using the
LABORAS1 system.34 Body weights over 16 weeks
were comparable between strains (data not shown).
Baseline behavior was measured 1 week prior to
surgical intervention in 32 Ccr7/ and 23 WT male
mice (Supplemental Fig. S1A). No differences between
strains were observed in time spent eating, grooming,
rearing, climbing or walking/running (locomotion).
Ccr7/ mice covered slightly less distance (median,
IQR¼134.m, 111.8–147.1, Supplemental Fig. S1B)
compared to WT mice (172m, 133.9–198.8, p< 0.005),
and spent less time drinking (169.8s, 67.8–260.9) than
WT mice (293.5s, 226.1–376.0, p< 0.005) over 14h.
However, average and maximum speeds during loco-
motion were similar in both strains.
Comparison of Behavior Post-DMM Compared to
Controls
Behavior measurements post-DMM were compared to
WT and Ccr7/ na€ve and sham controls, at each time
interval (Fig. 3; Supplemental Table S1). Significant
decreases post-DMM in WT activity compared to
controls were first observed 8-weeks (Supplemental
Table S1). After DMM surgery, WT mice climbed less
than na€ve controls (DMM: 954.1s, 727.5–1139 vs.
naive: 1758s, 1272–2106, p¼0.002), and covered less
Figure 2. Immunostaining for CCR7 in human
synovial tissues. Synovial biopsies obtained from
donors and patients were stained using an anti-
human CCR7 antibody (Materials and Methods).
Representative sections from an asymptomatic
donor, early OA patient undergoing meniscal
arthroscopy, and an advanced OA patient are
shown in A. Isotype control is shown in inset.
Staining was quantified using automated image
analysis and percent fractional area stained pre-
sented in B. Percent area stained was significantly
greater in the meniscal arthroscopy patients than
in asymptomatic donors.
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distance (DMM: 128.9m, 117.4–161.9 vs. naive:
183.3m, 157.3–190.4, p¼ 0.04ns with Bonferoni correc-
tion) (Fig. 3B and E). In contrast, decreases in activity
post-DMM compared to controls were not observed in
Ccr7/ mice until 16 weeks (Supplemental Table S1).
By 16 weeks, decreases were observed in locomotion
(Ccr7/ DMM: 2492s, 1634–3483 vs. na€ve: 4289s,
3047–5353, p¼0.02) (Fig. 3I) and distance traveled
(Ccr7/ DMM 149.4m, 100.1–205.8 vs. na€ve: 239.5m,
203.7–276.1, p¼ 0.013) (Fig. 3F).
Longitudinal Behavior Changes After DMM Surgery
We next analyzed longitudinal activity in DMM-
operated mice to test whether trajectories differed
between the two strains. Post-operative climbing activ-
ity in DMM operated WT mice trended down by
4 weeks and 8 weeks post-DMM in WT mice (p¼0.2,
Fig. 4A). In contrast, Ccr7/ mice showed no
decreases in climbing behavior post-DMM. Instead,
climbing activity significantly increased up to 8 weeks
post-surgery and thereafter decreased toward baseline.
Similar longitudinal trajectories were seen post-DMM
in locomotion (Fig. 4B) and distance traveled (Fig. 4C).
No clear differences in longitudinal patterns of eating,
drinking, grooming, or speed post-DMM surgery were
observed between strains (Supplemental Fig. S2).
Linear mixed-effects models were fitted to test
whether post-DMM activity trends differed between
strains. These models demonstrated that trajectories
differed significantly for climbing, locomotion and
distance traveled between strains (all p values for the
interactions of strain with time and time squared
<0.05, Table 2). For each activity, additional models
were fit to determine at which time point trends
diverged. For climbing and locomotion, the two
strains began to show different trajectories by 4 weeks
(p¼0.015 and 0.008, respectively), while distance
traveled diverged at 8 weeks (p¼0.025).
Cartilage Damage in Ccr7/ Mice After DMM Surgery
Cartilage pathology was first evaluated 6 weeks post-
surgery, a time point corresponding to early stage
disease.36 Consistent with other reports,32,33 cartilage
abnormalities at this point were very mild, and were
mostly limited to proteoglycan loss and surface fibrilla-
tion on the medial side (Fig. 5C and E). All un-
operated and sham controls were free of cartilage
damage. 6 weeks post-DMM, cartilage scores (summed
over all tibial and femoral surfaces) were slightly but
not statistically lower in Ccr7/ mice (median, IQR:
1.0, 0–3.5) compared to WT controls (4.0, 3.5–7.5,
p¼ 0.06, Fig. 5A). As expected, cartilage damage
Figure 3. Comparison of spontaneous behaviors after DMM surgery compared to control groups in the two strains. Spontaneous
activity was measured as described every 4 weeks up to 16 weeks post-DMM in the two strains of mice. Time spent climbing (A–C),
distance traveled (D–F), and locomotion (G–I), are depicted compared with sham and na€ve controls at the 4, 8, and 16 week time
points. In wild-type mice, time spent climbing post-DMM was significantly decreased by 8 weeks (B) compared to controls. A decreasing
trend was also seen at 8 weeks in distance traveled (E). Reduction in activity post-DMM compared to control groups was not observed
in CCR7/ mice until 12 weeks (decrease in locomotion, Supplemental Table S1), and was statistically significant by 16 weeks for
distance traveled (F) and locomotion (I). Medians, and IQRs are displayed. p values from Mann–Whitney U test compared to controls.
n¼ 7–10 mice per group.
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19-weeks after DMM surgery was more extensive than
at 6 weeks, indicating progression of OA (Fig. 5B and
D). At this stage, cartilage damage in DMM-operated
Ccr7/ mice (17.5, 10.25–31.0) and WT controls (17.0,
11–23.75, p> 0.99) was similar (Fig. 5B and F). Some
sham-operated animals from both strains exhibited
mild cartilage abnormalities at 19 weeks, albeit signifi-
cantly less than DMM-operated mice (Fig. 5B, p<0.02
for both WT and Ccr7/).
Osteophytosis After DMM Surgery in Ccr7/ Mice
Osteophytes were observed in DMM-operated mice
from both strains, while no osteophytosis occurred in
controls. 6 weeks post-DMM, osteophytes in WT mice
(Median, IQR: 150mm, 120–210) were statistically
larger than in Ccr7/ mice (100mm, 35–115, p¼ 0.04)
(Fig. 6A). No significant difference between strains was
observed 19 weeks post-DMM (Ccr7/ 50mm, 0–180
vs. WT: 135mm, 78–150, Fig. 6B, p¼0.37). Overall,
osteophyte size was highly variable in both strains.
Subchondral Bone Changes After DMM Surgery in Ccr7/
Compared to WT Mice
Subchondral bone changes are commonly associated
with articular cartilage lesions in OA.37–39 At 6 weeks
(Fig. 6C), subchondral bone sclerosis evaluated histolog-
ically31 increased in WT mice after DMM (median score,
IQR: DMM¼4.0, 2.0–5.0, na€ve: 0.0, 0–1.5, p¼0.024).
Interestingly, a similar increase was observed in sham-
operated mice (3.0, 2.0–4.5, p¼ 0.024). In contrast,
subchondral bone scores in Ccr7/ mice did not change
significantly in response to surgery (DMM: 3.0, 1.5–3.0;
sham: 1.0, 0.5–2.0; na€ve: 2.0, 1.5–3.0, p0.2). Bone
scores appeared higher in un-operated Ccr7/ (2.0,
1.5–3.0) compared to WT (0.0, 0.0–1.5, p¼ 0.056, ns). By
19 weeks post-surgery (Fig. 6D), no statistical differ-
ences were observed in DMM or sham-operated animals
compared to un-operated controls in either strain.
Between 6 and 19 weeks, median bone scores in
unoperated WT mice increased (6 week: 0.0, 0–1.5 vs.
19 week: 4.0, 2.0–4.0, p¼0.024), while scores in unoper-
ated Ccr7/ mice were unchanged (6 week: 2.0, 1.5–3.0
vs. 19 week: 1.0, 1.0–3.5, p¼0.42), indicating age-
related changes in WT mice.
MicroCT analysis of na€ve joints at time 0 confirmed
differences between strains in subchondral bone
(Fig. 7A, B, E, and F). Median bone mineral density in
Ccr7/ mice (968.5, 924–972.6mg HA/cm3) was 12.7%
higher than in WT mice (859.7, 846.5–892.9mgHA/
cm3, p¼ 0.004). Six weeks post-DMM, bone mineral
density increased in WT mice compared to na€ve age-
matched controls (DMM: 963, 957.2–974.6, na€ve: 905.1,
864.9–926.2, p¼0.029). Sham surgery resulted in simi-
lar increases (p¼ 0.029). In contrast, Ccr7/ mice
showed no differences (p¼0.73–0.90) in bone mineral
density in any group (Fig. 7B). By 19 weeks there were
no differences between groups in WT mice, while
bone mineral density trended lower in DMM and sham-
operated Ccr7/ mice (Ccr7/ Sham vs. Na€ve: 2.02%
Figure 4. Longitudinal activity patterns in wild-type and
Ccr7/ mice subjected to DMM surgery. Spontaneous activity
was measured pre-operatively and every 4 weeks up to 16 weeks
post-operatively using LABORAS platforms (details in materials
and methods). Median (IQR) time spent climbing (A), in locomo-
tion (B), and distance traveled (C) in 14h is presented. In wild-
type mice, time spent climbing (A) decreased slightly although
non-significantly after DMM surgery compared to baseline up to
8 weeks post-operatively. CCR7/ mice increased climbing
activity compared to baseline up to 8 weeks with decreases
thereafter. Similar longitudinal patterns were seen with locomo-
tion (B) and distance travelled (C). (p< 0.01 compared to pre-op
levels in same strain, #p<0.05 for trend difference between
strains using linear mixed effects models).
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decrease; p¼ 0.14, DMM vs. na€ve: 4.01% decrease;
p¼ 0.39). Percent bone volume fraction (%BV/TV)
showed similar trends. Mean %BV/TV was 12.9%
higher in Ccr7/ versus WT (p¼0.07, ns) at time 0
(Fig. 7C and D). Six weeks post-surgery, %BV/TV
increased in both WT DMM and sham groups although
this did not reach statistical significance (p¼0.06 for
both); there were no further changes by 19 weeks. %
BV/TV in Ccr7/ mice was not affected by surgery at
6 weeks, but by 19 weeks operated mice appeared to
have decreased %BV/TV (Fig. 7D), although this was
highly variable (p¼ns). WT un-operated mice showed
age-related increases in bone mineral density by 12.8%
and increases in %BV/TV by 10.5% from time 0 (age
Table 2. Linear Mixed-Effects Models Testing Longitudinal Activity Trends for Climbing, Locomotion, and Distance
Traveled in WT and Ccr7/ Mice Over 16 Weeks Post-DMM Surgery
p Value
Effect Climbing Locomotion Distance Traveled
Time 0.83 0.045 0.30
Time Squared 0.64 0.39 0.97
Strain 0.44 0.62 0.22
TimeStrain 0.0001 0.044 0.011
Time SquaredStrain 0.0002 0.014 0.009
Figure 5. Ccr7 deficient mice show reduced cartilage degeneration at 6 weeks, but not 19 weeks after DMM surgery. Groups of 5–10
mice were subjected to DMM or sham surgery at 10–12 weeks of age, or left unoperated (na€ve). At 6 weeks and 19 weeks post-surgery,
knee joints were dissected and prepared for histologic analysis. Total cartilage degeneration scores in WT (black squares) and Ccr7
knockout mice (red circles) at (A) 6 weeks and (B) 19 weeks post-surgery are shown. p< 0.025 compared to DMM operated mice of the
same strain (Kruskal–Wallis followed by Mann–Whitney U-test). Representative photomicrographs of knee histopathology are depicted
in panels C–E. (C) Wild-type at 6 weeks post-DMM, (D) wild-type at 19 weeks post-DMM, (E) Ccr7/ at 6 weeks post-DMM, (F) Ccr7/ at 19 weeks post-DMM.
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10–12 weeks) to 19 weeks (age 29–31 weeks)
(Fig. 7A and C). Un-operated CCR7/ mice displayed
no significant age-related changes.
Synovial Inflammation in WT and Ccr7/ Mice After
DMM Surgery
Evaluation of synovial hyperplasia showed very mild
changes post-DMM (Median, IQR at 6 weeks WT: 1.0,
0.5–1.5, Ccr7/: 1.0, 1.0–1.0, and 19 weeks WT: 0.0,
0.0–1.0, Ccr7/: 0.0, 0.0–1.0), which were not statisti-
cally different from controls (Fig. 8A and B). Addition-
ally, we used mRNA analysis of CD68 (a macrophage
marker) to evaluate low-grade inflammation in this
model. In WT mice, CD68 mRNA levels increased in
DMM-operated limbs 1, 2, and 4 weeks post-surgery
(4 weeks: 21.11, 16.06–27.66) compared to unoperated
limbs (1.63, 0.71–5.81, p¼0.13) (Fig. 8C). Similar
increases in CD68 expression were observed post-
DMM in Ccr7/ mice (4 weeks: 18.30, 12.71–35.34,
compared to unoperated limbs 5.77, 4.39–9.33,
p¼ 0.03) (Fig. 8D).
DISCUSSION
There are often discrepancies between structural and
symptomatic signs of OA.40 The paucity of studies
evaluating structural and functional outcomes in pre-
clinical models of OA poses a significant limitation to
translational efforts in this field.41 To this end, we have
comprehensively characterized joint pathology (carti-
lage erosion, synovial change, subchondral bone sclero-
sis, and osteophytosis) and functional manifestations
(spontaneous behavior), to test if absence of Ccr7
influences disease after DMM surgery. Ccr7/ mice
showed 75% less cartilage erosion and 50% smaller
osteophytes 6 weeks post-DMM surgery. However, this
minimal early protection was not sustained by
19 weeks, and clinical significance of this finding is not
clear. Differences in activity deficits, however, were
more pronounced and delayed after DMM in the
absence of Ccr7, suggesting a role for this receptor in
symptom development. Only spontaneous locomotor
activities were affected, while biologically driven activi-
ties (eating and drinking) were preserved.42 Decreased
Figure 6. Histologic bone changes post-DMM in wild-type and Ccr7/ mice. Osteophyte size (panels A and B) and subchondral bone
sclerosis (panels C and D) were scored as described. Osteophyte size and bone scores in WT and Ccr7/ mice (A and C) at 6 weeks
post-surgery and (B and D) 19 weeks post-surgery are shown. p-values from Kruskal–Wallis followed by Mann–Whitney U-test.
Representative histopathology is shown of the medial tibial plateau from (E) an unoperated WT knee at the 6 week time point (no
osteophyte, subchondral bone score of 0) and (F) a DMM-operated WT knee at 6 weeks (osteophyte¼ 200 micron, subchondral bone
score¼ 5). White arrow¼ subchondral bony sclerosis, red arrow¼marginal osteophyte.
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spontaneous activity after DMM surgery is consistent
with earlier reports demonstrating these outcomes to
be surrogate signs of movement-provoked pain.35,42
Longitudinal analysis demonstrated that climbing ac-
tivity decreased in WT mice post-DMM in the early
stages of disease (4 weeks) and showed functional
relevance (decreased distance traveled) by 8 weeks. In
contrast, functionally relevant activity decreases were
not observed in Ccr7/ mice until 16 weeks after
DMM. This delay paralleled delays in cartilage and
bone changes, suggesting an association of these out-
comes with disease in this model.41
This study points out the importance of assessing
disease features at multiple stages as delay could have
been interpreted as protection if evaluated at one time
point, and age-related changes would not have been
apparent. Therapeutics that delay symptomatic and/or
structural progression may be quite useful to offset the
need for arthroplasty in younger patients.43 Since
instability caused by DMM was not corrected in this
model, OA development in Ccr7/ mice at later stages
could be due to mechanical dysfunction over-riding the
initial protection. Our results emphasize the need to
elucidate mechanisms relevant to specific phases of
disease (i.e., development, progression) to enhance
understanding of structure-function correlation.44
Analysis of subchondral bone, a major site of remodel-
ing in human OA,45 revealed additional insights.
Figure 7. Subchondral bone volume and mineral density measured by microCT in wild-type and Ccr7 deficient mice. MicroCT scans
of na€ve joints at 10–12 weeks of age (time 0), and na€ve and operated (sham or DMM) joints at 6 and 19 weeks after surgery were
performed. n¼5 mice per group (final numbers analyzed are 3–5 per group, as some scans contained artifacts that precluded analysis).
Panels A and C describe trends in bone mineral density (BMD) and bone volume fraction (%BV/TV) in wild-type mice. Panels B and D
indicate trends in BMD and % BV/TV in Ccr7/ mice. Representative 2D microCT slices were chosen from 10 to 12-week-old (time 0)
un-operated wild-type (E) and Ccr7/ (F) mice.
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Changes to subchondral bone may alter biomechanics of
the joint and transmit pathologic mechanical signals to
overlying articular cartilage, contributing to degrada-
tion.46 Both histopathology and microCT revealed in-
creased subchondral bone sclerosis in WT mice that
occurred early (6 weeks) in response to DMM as
previously published,47 but that did not progress by
19 weeks. Unexpectedly, we observed alterations in
sham-operated animals not previously reported. Other
reports have often compared subchondral bone quality
in DMM-operated joints to na€ve joints or a skin incision
without arthrotomy.48 Our analysis revealed that sub-
chondral bone remodeling may be a response to arthrot-
omy in this model, as it occurred independent of other
structural signs of disease. This is consistent with
findings from the collagenase model of murine OA,49
suggesting that subchondral bone changes alone may
not be sufficient to drive cartilage pathology in these two
models. The expected response to decreased activity (and
therefore loading) would be a decrease in bone volume
and density,50 but WT mice showed an increase in these
outcomes after DMM during the time frame that activity
decreased. This suggests that the bone response in this
model is pathologic and unlikely due to activity changes.
In contrast to WT, Ccr7/ mice did not show
increases in subchondral bone outcomes 6 weeks post-
DMM compared to age-matched na€ve controls. Fur-
thermore, un-operated WT mice displayed significant
increases in subchondral bone measures as a function
of age, while lack of Ccr7 diminished any age
response. Ccr7/ mice started with increased sub-
chondral bone volume and density prior to surgical
intervention (time 0), which may explain their de-
creased response to surgery or age. Ccr7/ mice
were more active during the early time frame after
DMM but their bone density did not increase, again
suggesting that changes were not solely a result of
activity. The early pathologic response seen in the
model was prevented in the absence of Ccr7, which
was interesting as there is no known role for Ccr7
signaling in bone remodeling. Ccr7/ mice did show
signs of bone turnover in response to surgery, but
this response was delayed and resulted in net loss
rather than gain in bone density and volume
(Fig. 7D). Although limited by small numbers of
specimens, taken together our results implicate Ccr7
in subchondral bone changes in this model, as well as
in the context of aging.
Figure 8. Synovial response to DMM injury in both strains of mice. Synovial hyperplasia in wild-type (WT) and Ccr7/ mice at
6 weeks (A) and 19 weeks (B) post-surgery. Hyperplasia was scored as described just superior to the medial meniscus. No significant
differences were observed between groups. Gene expression analysis of CD68 transcript levels in knee synovial capsular tissue up to
4 weeks post-DMM in WT (C) and Ccr7 deficient mice (D). mRNA copy number measured by droplet digital PCR and normalized to
number of TBP transcripts. p< 0.05 compared to left un-operated side, Wilcoxon matched-pairs signed-rank test. #p<0.017 compared
to baseline levels, Mann–Whitney U-test.
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There are several limitations to this study. Only
spontaneous activity was measured as a symptomatic
outcome in this study. Other methods of assessing
weight-bearing pain such as static weight-bearing or
gait analysis may be more sensitive to detecting
change even before activity levels decline, and might
have revealed more substantial strain-related differ-
ences. Moreover, reductions in spontaneous activity
may be reflective of both movement-related pain and
mechanical restriction. However, we chose this assess-
ment due the relevance of activity disruption to
clinical disability. Evaluation of osteophyte size was
performed on thin-sections, which does not allow
determination of osteophyte numbers. Differences in
cartilage damage and osteophytosis 6 weeks post-
DMM were of small magnitude and could be due to
variability in the model. Still, average cartilage scores
were 75% lower in deficient mice at 6 weeks, and there
were also delays in subchondral bone and functional
deficits. As disease in humans reflects both structural
joint pathology and symptomatic joint dysfunction
that do not always correspond in severity, this study
also points to the importance of evaluating multiple
disease manifestations in OA models. Our data sug-
gests a stronger role for Ccr7 contributing to bony
changes and symptomatic outcomes in this model
rather than cartilage damage.
We did not find a significant effect of Ccr7 defi-
ciency on early synovial changes in this model. Synovi-
tis in this model is extremely mild, so testing in other
models with a greater inflammatory component may
be necessary. Interestingly though, Ccr7/ mice had
increased subchondral bone volume and density at
baseline which could be partially responsible for the
early protection in this model. Alternatively, certain
chemokine receptors may have a direct influence on
nociception.42 Understanding the specific molecular
pathways that delay structural and symptomatic dis-
ease manifestations will be critical to develop pharma-
cologic agents that can significantly slow OA
progression, and relieve OA joint pain and disability.
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